✦ LIBER ✦

PIN10 ECOMOMIC EVALUATION OF DAPTOMYCIN COMPARE WITH STANDARD THERAPY IN THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA WITH OR WITHOUT ENDOCARDITIS IN COLOMBIA

✍ Scribed by F. Rosso; R. Soto; J.G. Ariza; J.D. Rueda; D. Rosselli

Book ID: 119309411
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 57 KB
Volume: 14
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2011.02.642

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PIN26 A COST-EFFECTIVENESS ANALYSIS ON T

PIN26 A COST-EFFECTIVENESS ANALYSIS ON THE USE OF DAPTOMYCIN FOR THE TREATMENT OF BACTEREMIA AND INFECTIVE ENDOCARDITIS IN PATIENTS WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTION IN MEXICO

✍ F. García-Contreras; M. Martinez Revelles; B. Briones 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Multicenter Evaluation of the Clinical O

Multicenter Evaluation of the Clinical Outcomes of Daptomycin with and without Concomitant -Lactams in Patients with Staphylococcus aureus Bacteremia and Mild to Moderate Renal Impairment

✍ Moise, P. A.; Amodio-Groton, M.; Rashid, M.; Lamp, K. C.; Hoffman-Roberts, H. L. 📂 Article 📅 2012 🏛 American Society for Microbiology 🌐 English ⚖ 595 KB

PIN3 Health Outcomes With Daptomycin (DA

PIN3 Health Outcomes With Daptomycin (DAP) in the Treatment of Methicillin Resistant Staphylococcus Aureus Bacteremia (MRSA-B) With Vancomycin (VAN) Minimum Inhibitory Concentration (MIC) = 2 μG/Ml

✍ Forrest, G.; Larson, K.; Crompton, M.; Patel, H.; Boening, A.J. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Hypofractionated Radiation Therapy With

Hypofractionated Radiation Therapy With or Without Temozolomide Compared to Standard of Care in the Treatment of Glioblastoma: Results From a Single Institution

✍ Azoulay, M.; Mansure, J.; Shenouda, G.; Patyka, M.; Sabri, S.; Abdulkarim, B. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 54 KB

8LBA Biomarker evaluation in the randomi

8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

✍ B. Johnson; V. Miller; L. Amler; H. Stern; C. Soh; P. O'Connor; F. Kabbinavar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB